Skip to main content

Table 5 Estimated disease burden impacts of no vaccination, PCV13 2+1 and PHiD-CV 2+1 vaccination programs

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

  No vaccination PCV13 PHiD-CV PHiD-CV versus no vaccination PHiD-CV versus PCV13
IPD cases (acute episodes) 2444 1295 1335 –1109 +40
 Meningitis 1021 533 550 –471 +17
 Bacteremia 1423 762 785 –638 +23
All-cause pneumonia cases (acute episodes) 534,819 510,143 510,140 –24,679 –3
AOM cases (acute episodes) 565,764 522,825 492,824 –72,940 –30,001
Pneumococcal deaths 239 132 136 –103 +4
 IPD 209 107 111 –98 +4
 Pneumonia 30 25 25 –5 0
  1. AOM acute otitis media, IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine
  2. In Malaysia over 10 years for a birth cohort of 508,774